Results 191 to 200 of about 151,276 (329)

Retinoblastoma and deletion D (14) syndrome.

open access: bronze, 1969
Miriam G. Wilson   +2 more
openalex   +1 more source

Mechanical Thrombectomy in Two Children Under the Age of One Year

open access: yesClinical Case Reports, Volume 13, Issue 10, October 2025.
ABSTRACT This case series examines mechanical thrombectomy (MT) with thromboaspiration in two infants under 1 year, a rarely performed procedure due to ethical challenges and limited data. Both cases involved thromboembolic complications during intra‐arterial chemotherapy for retinoblastoma.
Erensu Mengüşoğlu   +4 more
wiley   +1 more source

Lactiplantibacillus plantarum OLL2712 Protects From the Intestinal Dysfunction in D‐Galactose Induced Senescent Cells

open access: yesFood Science &Nutrition, Volume 13, Issue 10, October 2025.
Lactiplantibacillus plantarum OLL2712 (OLL2712) on intestinal dysfunction related to cellular senescence was investigated. Using D‐galactose to induce senescence in Caco‐2 cells, OLL2712 suppressed cellular senescence and restored barrier integrity, while microarray analysis revealed it upregulated signaling pathways related to antioxidants and ...
Yumiko Watanabe‐Yasuoka   +5 more
wiley   +1 more source

Prognostic impact of p16 and high‐risk HPV DNA in ~1300 patients with vulvar cancer

open access: yesInternational Journal of Cancer, Volume 157, Issue 7, Page 1354-1362, 1 October 2025.
What's New? Vulvar cancer (VSCC) is rare, and little is known about early prognostic factors that could contribute to an individualized treatment plan. About 30%–40% of VSCCs are associated with human papillomavirus (HPV). Here, the authors investigated the prognostic influence of p16 status in VSCC in a large cohort of 1300 patients.
Susanne K. Kjær   +14 more
wiley   +1 more source

Retinoblastoma, the visible CNS tumor: A review

open access: yesJournal of Neuroscience Research, 2019
H. Dimaras, T. Corson
semanticscholar   +1 more source

Efficacy, Safety, and Biomarkers of Neoadjuvant Dalpiciclib (CDK4/6 inhibitor) plus Aromatase Inhibitors in Operable HER2‐Negative Luminal B Breast Cancer: A Prospective, Single‐Center, Single‐Arm, Phase II Trial (DANCER)

open access: yesMedComm, Volume 6, Issue 10, October 2025.
DANCER (NCT05640778) was a circulating tumor DNA (ctDNA)‐directed, single‐arm, phase II trial investigating the clinical activity of dalpiciclib combined with aromatase inhibitors as a neoadjuvant regimen for operable human epidermal growth factor receptor 2 (HER2)‐negative luminal B breast cancer. Although a high complete cell cycle arrest (CCCA) rate
Yunxiang Zhou   +21 more
wiley   +1 more source

Breast Cancer: Molecular Pathogenesis and Targeted Therapy

open access: yesMedComm, Volume 6, Issue 10, October 2025.
Dysregulation signaling pathways in various breast cancer subtypes and their targeting using different inhibitors. ABSTRACT Breast cancer (BC) is the most prevalent cancer in women and remains the leading cause of cancer‐related mortality globally.
Md Abdus Samad   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy